Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Cefalexin monohydrate
Virbac S.A.
QJ01DB01
Cefalexin monohydrate
300 mg/tablet
Tablet
POM: Prescription Only Medicine as defined in relevant national legislation
Dogs
cefalexin
Antibacterial
Authorised
1988-10-01
Health Products Regulatory Authority 19 January 2022 CRN00CHP7 Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rilexine 300 mg Tablets for dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: ACTIVE SUBSTANCE: Cefalexin 300 mg (as Cefalexin Monohydrate) For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablets. Creamy oblong tablet with small brown spots marked with a score line. The tablets can be divided into halves. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of bacterial skin infections in dogs (including deep and superficial pyodermas) caused by organisms susceptible to Cefalexin. For the treatment of urinary-tract infections in dogs (including nephritis and cystitis) caused by organisms susceptible to Cefalexin. 4.3 CONTRAINDICATIONS Do not use in animals known to be hypersensitive to penicillins and cephalosporins. Do not use in rabbits, guinea pigs, hamsters and gerbils. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals As with other antibiotics which are excreted mainly by the kidneys, unnecessary accumulation may occur in the body when renal function is impaired. In case of known renal insufficiency, the dose should be reduced and antimicrobials known to be nephrotoxic should not be administered concurrently. This product should not be used to treat puppies of less than 1 kg of bodyweight. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to Cefalexin and may decrease the effectiveness of treatment with penicillins due to the potential for cross-resistance. Health Products Regulatory Authority 19 January 2022 CRN00CHP7 Page 2 of 4 Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local epidemiological informa Read the complete document